Literature DB >> 23420725

Clinical challenges of an oligosecretory plasma cell dyscrasia.

Luís Rodrigues1, Marta Neves, Helena Sá, Mário Campos.   

Abstract

Light chain deposition disease (LCDD) and immunoglobulin light chain (AL) amyloidosis are uncommon, and heterogeneous clonal plasma cell (PC) proliferative disorders defined by the different biochemical characteristics of the underlying anomalous immunoglobulin. The deposits are usually multisystemic and the two diseases can coexist. The diagnosis is sometimes made difficult by the absence of a detectable paraprotein by routine immunofixation techniques, and the use of serum-free light chain (FLC) immunoassay brought new value in terms of their diagnosis, prognosis and assessment of treatment response. Association of LCDD and AL amyloidosis with multiple myeloma (MM) at the time of diagnosis is common, but further progression to this condition is considered rare. We present a case of a patient diagnosed with systemic LCDD and AL amyloidosis of atypical biochemical characteristics, with no paraprotein detected in immunoelectrophoresis and immunofixation techniques, who progressed to MM in the later course of her disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23420725      PMCID: PMC3604379          DOI: 10.1136/bcr-2012-008169

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.

Authors:  R Khurana; J R Gillespie; A Talapatra; L J Minert; C Ionescu-Zanetti; I Millett; A L Fink
Journal:  Biochemistry       Date:  2001-03-27       Impact factor: 3.162

Review 2.  Towards understanding the structure-function relationship of human amyloid disease.

Authors:  Chris Dealwis; Jonathan Wall
Journal:  Curr Drug Targets       Date:  2004-02       Impact factor: 3.465

3.  Primary systemic amyloidosis with delayed progression to multiple myeloma.

Authors:  S V Rajkumar; M A Gertz; R A Kyle
Journal:  Cancer       Date:  1998-04-15       Impact factor: 6.860

4.  Renal monoclonal immunoglobulin deposition disease: the disease spectrum.

Authors:  Julie Lin; Glen S Markowitz; Anthony M Valeri; Neeraja Kambham; William H Sherman; Gerald B Appel; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

Review 5.  Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.

Authors:  Claudio Pozzi; Marco D'Amico; Giovanni B Fogazzi; Simona Curioni; Franco Ferrario; Sonia Pasquali; Giacomo Quattrocchio; Cristiana Rollino; Siro Segagni; Francesco Locatelli
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

6.  Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy.

Authors:  G Moroni; G Banfi; A Montoli; A Bucci; T Bertani; M Ravelli; C Pozzi; M Leonelli; A Lupo; A Volpi
Journal:  Clin Nephrol       Date:  1992-08       Impact factor: 0.975

7.  Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Authors:  Helen J Lachmann; Ruth Gallimore; Julian D Gillmore; Hugh D Carr-Smith; Arthur R Bradwell; Mark B Pepys; Philip N Hawkins
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

Review 8.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

9.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

10.  Light-heavy chain deposition disease progressing to multiple myeloma.

Authors:  D Daliani; D Weber; R Alexanian
Journal:  Am J Hematol       Date:  1995-12       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.